临床试验

SNIFF - Combo INI+EMPA Trial

NCT：NCT05081219 · COMPLETED

NCT编号NCT05081219

状态COMPLETED

开始日期2021-09-14

完成时间2024-09-17

SponsorWake Forest University Health Sciences (OTHER)

First posted2021-10-18

Last updated2026-10-07

简要摘要

The proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin, to correct bioenergetic and vascular dysfunction in adults with preclinical Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI) or early AD.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。